IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Raised by Cabot Wealth Management Inc.

Cabot Wealth Management Inc. increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,715 shares of the company’s stock after purchasing an additional 85 shares during the quarter. Cabot Wealth Management Inc.’s holdings in IDEXX Laboratories were worth $2,887,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Riverview Trust Co purchased a new position in shares of IDEXX Laboratories in the first quarter worth approximately $26,000. Crewe Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at $26,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $27,000. Institutional & Family Asset Management LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of IDEXX Laboratories during the second quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. BTIG Research began coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $574.13.

IDEXX Laboratories Stock Down 0.9 %

Shares of NASDAQ IDXX traded down $4.08 during mid-day trading on Tuesday, reaching $473.92. 555,788 shares of the company traded hands, compared to its average volume of 467,800. The company’s fifty day moving average is $488.46 and its two-hundred day moving average is $493.17. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The stock has a market cap of $39.14 billion, a PE ratio of 46.27, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the business earned $2.67 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.